Skip to Content
Merck
CN

RAB0050

Human TARC / CCL17 ELISA Kit

for serum, plasma, cell culture supernatant and urine

Synonym(s):

C-C motif chemokine 17 , CC chemokine TARC, CCL17, TARC

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

NACRES:
NA.32
UNSPSC Code:
41116158
Gene information:
human ... CCL17(6361)
Input:
sample type urine
sample type serum
sample type cell culture supernatant(s)
sample type plasma
Species reactivity:
human
Storage temp.:
−20°C
Shipped in:
wet ice

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

species reactivity

human

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable, capture ELISA: suitable

input

sample type urine
sample type serum
sample type cell culture supernatant(s)
sample type plasma

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 5 pg/mL
standard curve range: 10.2-2500 pg/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... CCL17(6361)

Related Categories

General description

The Human TARC (Thymus and Activation Regulated Chemokine) ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human TARC in serum, plasma, cell culture supernatants and urine.

Immunogen

Recombinant Human TARC

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Biochem/physiol Actions

C-C motif chemokine ligand 17 (CCL17), also known as thymus and activation-regulated chemokine (TARC), is produced by bronchial epithelial cells, endothelial cells and myeloid dendritic cells. This chemokine is a ligand for CC chemokine receptors 4 and 8. It is involved in recruiting type 2 T-helper cells (Th2) cells and in activating other antigen-presenting cells. CCL17 has been linked to atopic dermatitis and asthma.

Other Notes

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Kit Components Also Available Separately

Product No.
Description
SDS
  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)SDS
  • RABELADCELISA 1X Assay/Sample Diluent Buffer C (Item L)SDS
  • RABSTOP3ELISA Stop Solution (Item I)SDS
  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDS
  • RABWASH420X Wash Buffer (Item B)SDS

pictograms

Corrosion
GHS05

signalword

Warning

hcodes

H290

Hazard Classifications

Met. Corr. 1

Storage Class

8A - Combustible corrosive hazardous materials

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0314K0236
1220J0236
1102J0236
0401I0236
0625H0236

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Targeting CD1c-expressing classical dendritic cells to prevent thymus and activation-regulated chemokine (TARC)-mediated T-cell chemotaxis in rheumatoid arthritis
MR Hillen
Scandinavian Journal of Rheumatology. Supplement (2017)
Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma
Ying Xiong
BMC Cancer (2017)
Anna Guidetti et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(22), 5641-5651 (2014-09-23)
To evaluate safety and activity of perifosine and sorafenib combination therapy in patients with lymphoproliferative diseases. Patients with relapsed and refractory lymphoproliferative diseases received perifosine (50 mg twice daily) for 1 month. Patients achieving less than partial response (PR) after
Karen Knipping et al.
Acta paediatrica (Oslo, Norway : 1992), 103(7), 766-774 (2014-04-05)
Eosinophilic oesophagitis (EO) is an emerging worldwide disease, closely associated with male gender and allergic disorders. This study investigated the distribution of allergy markers in a cohort of children with EO. We analysed allergy markers in 91 children (62 males

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service